ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
3.71B
Market cap3.71B
Price-Earnings ratio
9.45
Price-Earnings ratio9.45
Dividend yield
Dividend yield
Average volume
1.49M
Average volume1.49M
High today
$22.60
High today$22.60
Low today
$21.42
Low today$21.42
Open price
$22.52
Open price$22.52
Volume
841.56K
Volume841.56K
52 Week high
$28.35
52 Week high$28.35
52 Week low
$13.73
52 Week low$13.73

Stock Snapshot

ACADIA Pharmaceuticals(ACAD) stock is priced at $21.74, giving the company a market capitalization of 3.71B. It carries a P/E multiple of 9.45.

As of 2026-04-12, ACADIA Pharmaceuticals(ACAD) stock has fluctuated between $21.42 and $22.60. The current price stands at $21.74, placing the stock +1.5% above today's low and -3.8% off the high.

The ACADIA Pharmaceuticals(ACAD)'s current trading volume is 841.56K, compared to an average daily volume of 1.49M.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $28.35 and a 52-week low of $13.73.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $28.35 and a 52-week low of $13.73.

ACAD News

Simply Wall St 5d
Will DAYBUE STIX Launch Deepen Acadia Pharmaceuticals' Stake in Rett Syndrome Treatment Narrative

Acadia Pharmaceuticals has recently confirmed that DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for Rett syndrome in patients age...

Will DAYBUE STIX Launch Deepen Acadia Pharmaceuticals' Stake in Rett Syndrome Treatment Narrative
TipRanks 5d
Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital

RBC Capital lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $30 and keeps an Outperform rating on the shares as part of the firm’s...

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
19%
Sell
4.8%

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.